NRG And TerThera Cooperate To Secure Terbium-161 Supply Last week, NRG (ENS Corporate Member) and TerThera signed an agreement for irradiation services in the High Flux Reactor in Petten to produce Terbium-161. The non-carrier-added (NCA) Terbium-161 is produced by neutron irradiation of highly enriched Gadolinium-160 targets in the Dutch research reactor. Terbium-161 is a promising novel…
“Nuclear medicine has a great unexplored potential” Interview with Anthony Waked, PhD Fellow at SCK CEN – Belgian Nuclear Research Centre and the University of Liège, Belgium In the past decade, research has made tremendous progress and medical isotopes are expected to become a vital tool in the treatment of many types of cancers in…
SCK CEN Announced A New Partnership To Accelerate The Fight Against Cancer The Belgian Nuclear Research Centre SCK CEN (ENS Corporate Member) announced that the US-based SpectronRx will open its first European radiolabeling facility for sorely needed medical radioisotopes. The facility will be established on the premises of the research centre in Mol, Belgium. Both…
SCK CEN And TerThera Collaborate To Secure Terbium-161 Supply SCK CEN (ENS Corporate Member) and TerThera signed an agreement to handle together the production process of Terbium-161, a promising novel radionuclide for cancer treatment. Terbium-161 can meet the growing demand in cancer healthcare, exhibiting comparable (radio)chemical characteristics to known radiolanthanides. Targeted cancer therapies with Terbium-161 are expected…
PSI Leads New Research To Fight Metastatic Prostate Cancer Researchers at the Paul Scherrer Institute (ENS Corporate Member, PSI) are developing a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug, studied by a research consortium involving PSI, the University Hospital Basel and ETH Zurich, is now being…
PSI Developed A New Promising Radiopharmaceutical Successfully Tested A promising radiopharmaceutical against metastatic neuroendocrine tumours has been successfully tested for the first time in patients at the University Hospital Basel, Switzerland. The new radionuclide terbium-161 was developed at the Paul Scherrer Institute (PSI, ENS Corporate Member). This isotope has the property that when the radioisotope…
“Advancing Healthcare” Exploring the Frontiers of Nuclear Medicine In the field of healthcare innovation, nuclear medicine and radiopharmaceuticals stand out for their remarkable contributions to diagnosis and treatment. These technologies offer personalized approaches and targeted therapies, which are revolutionizing patient care. However, to ensure access to these cutting-edge treatments for all, it’s crucial to support…
NRG|PALLAS and Curium Expand Cooperation in Lu-177 Production NRGIPALLAS (ENS Corporate Member) and Curium have signed a long-term agreement to expand the current cooperation to include the production of lutetium-177 (Lu-177). This agreement will enable Curium to supply about 70,000 doses of Lu-177 annually, which will help about 14,000 patients per year. Curium and NRG…
NRG|PALLAS and TAG1 Inc. Partner To Expand Pb-212 Production NRGIPALLAS (ENS Corporate Member) and TAG1 Inc. have signed a multi-year partnership to secure a critical supply of radium-224 for the production of lead-212 (Pb-212) isotope. This agreement aims to strengthen the supply chain for innovative radiopharmaceutical cancer treatments, including Targeted Alpha Therapies (TATs), which hold great…